Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer SKYSCRAPER-02, the first randomized study of tiragolumab...
-
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma (DLBCL) over the standard of care in...
-
First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presentedEvrysdi data...
-
Basel, 23 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the donation of additional medicines and diagnostics to Ukraine. Beyond the already communicated 150,000 packs of an...
-
Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and DeltaThe World...
-
Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events decreased over the same periodPart 2 of SUNFISH showed...
-
All proposals of the Board of Directors approvedChristoph Franz as Chairman of the Roche Board of Directors and all other Board members standing for re-election approved; Jemilah Mahmood elected as a...
-
Adoption de toutes les propositions du Conseil d’administrationChristoph Franz est réélu président du Conseil d’administration, et tous les autres membres du Conseil d’administration candidats à leur...
-
Alle Anträge des Verwaltungsrates genehmigtChristoph Franz erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Verwaltungsrätinnen und Verwaltungsräte bestätigt;...
-
Evrysdi® (risdiplam) data further confirm long-term efficacy and safety data in a broad range of people with spinal muscular atrophy (SMA)Latest interim results from the RAINBOWFISH study demonstrate...